Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma

Lung Cancer

Volumn 100, Issue , 2016, Pages 1-4

  Guibert, Nicolas ^a,b,d   Pradines, Anne ^b,c   Farella, Magali ^b,c   Casanova, Anne ^b,c   Gouin, Sandrine ^a   Keller, Laura ^b,c,d   Favre, Gilles ^b,c,d   Mazieres, Julien ^a,b,d  

^a SERVICE DE PNEUMOLOGIE   (France)

^b CANCER RESEARCH CENTER OF TOULOUSE   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Circulating tumor cells; Circulating tumor DNA; KRAS mutation; Monitoring of response; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CHLOROPLAST DNA; CISPLATIN; DNA; DOCETAXEL; ERLOTINIB; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; NAVELBINE; PACLITAXEL; PEMETREXED; KRAS PROTEIN, HUMAN; PROTEIN P21;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DNA EXTRACTION; FEMALE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG BIOPSY; MALE; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TREATMENT RESPONSE; TUMOR VOLUME; ADENOCARCINOMA; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES; TREATMENT OUTCOME; TUMOR EMBOLISM;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASTIC CELLS, CIRCULATING; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS P21(RAS); TREATMENT OUTCOME;

EID: 84979220830     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.07.021     Document Type: Article

References (20)

1. [1] Guibert, N., Ilie, M., Long, E., Hofman, V., Bouhlel, L., Brest, P., et al. KRAS mutations in lung adenocarcinoma: molecular and epidemiological characteristics, methods for detection, and therapeutic strategy perspectives. Curr. Mol. Med. 15:5 (2015), 418–432.
2. [2] Patricelli, M.P., Janes, M.R., Li, L.-S., Hansen, R., Peters, U., Kessler, L.V., et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 6:March (3) (2016), 316–329.
3. [3] Ilie, M., Hofman, V., Long, E., et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?. Ann. Transl. Med., 2(November (11)), 2014, 107.
4. [4] Maheswaran, S., Sequist, L.V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C.V., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359:July (4) (2008), 366–377.
5. [5] Ilie, M., Long, E., Butori, C., Hofman, V., Coelle, C., Mauro, V., et al. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann. Oncol. 23:November (11) (2012), 2907–2913.
6. [6] Newman, A.M., Bratman, S.V., To, J., Wynne, J.F., Eclov, N.C.W., Modlin, L.A., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20:May (5) (2014), 548–554.
7. [7] Rainer, T.H., Lam, N.Y.L., Circulating nucleic acids and critical illness. Ann. N. Y. Acad. Sci. 1075:September (2006), 271–277.
8. [8] Oxnard, G.R., Paweletz, C.P., Kuang, Y., Mach, S.L., O'Connell, A., Messineo, M.M., et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 20:March (6) (2014), 1698–1705.
9. [9] Kim, S.T., Sung, J.S., Jo, U.H., Park, K.H., Shin, S.W., Kim, Y.H., Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?. Med. Oncol., 30(March (1)), 2013, 328.
10. [10] Nygaard, A.D., Garm Spindler, K.-L., Pallisgaard, N., Andersen, R.F., Jakobsen, A., The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer 79:March (3) (2013), 312–317.
11. [11] Lecomte, T., Ceze, N., Dorval, E., et al. Circulating free tumor DNA and colorectal cancer. Gastroenterol. Clin. Biol. 34 (2010), 662–681.
12. [12] Sorenson, G.D., Pribish, D.M., Valone, F.H., et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol. Biomarkers Prev. 3 (1994), 67–71.
13. [13] Gormally, E., Vineis, P., Matulo, G., et al. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res. 66:July (13) (2006), 6871–6876.
14. [14] Guibert, N., Pradines, A., Casanova, A., Farella, M., Keller, L., Soria, J.-C., et al. Detection and monitoring of the BRAF mutation in circulating tumor cells and circulating tumor DNA in BRAF-mutated lung adenocarcinoma. J. Thorac. Oncol., 7(May), 2016.
15. [15] Wang, S., An, T., Wang, J., Zhao, J., Wang, Z., Zhuo, M., et al. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 16:February (4) (2010), 1324–1330.
16. [16] Zhang, H., Liu, D., Li, S., Zheng, Y., Yang, X., Li, X., et al. Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology. J. Mol. Diagn. 15:November (6) (2013), 819–826.
17. [17] Freidin, M.B., Freydina, D.V., Leung, M., Montero Fernandez, A., Nicholson, A.G., Lim, E., Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. Clin. Chem. 61:October (10) (2015), 1299–1304.
18. [18] Del Re, M., Tiseo, M., Bordi, P., D'Incecco, A., Camerini, A., Petrini, I., et al. Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. Oncotarget(January), 2016.
19. [19] Spigel, D.R., Schrock, A.B., Fabrizio, D., et al. Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. J. Clin. Oncol., 34(May (15_Suppl.)), 2016, 9017 (Meeting Abstracts).
20. [20] Li, D., Zhu, X., Li, N., Li, Y., Correlation of PD-L1 expression with EGFR, KRAS, or ALK alterations and with survival of non-small cell lung cancer (NSCLC) treated with EGFR-TKIs: a meta-analysis of published trials. J. Clin. Oncol., 34(May (15_Suppl.)), 2016, e20576 ASCO Annual Meeting (June 3–7, 2016).